This page is intended for UK healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here.
This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.
Adverse events reporting information can be found in the footer of this page.
The role of MDT in NET management: when to consider PRRT in GEP-NETs
Dr Christos Toumpanakis
Dr Christos Toumpanakis, Consultant in...
Dr Gopi Gnanasegaran
In this short introductory video, Dr Gopi Gnanasegaran introduces session 2 of the PRRT Masterclass 2021.
//-->Live panel discussion and audience Q&A
Listen to the second instalment of the PRRT Masterclass panel discussion with Dr John Buscombe; who is joined by Dr...
The role of the NET nurse in the PRRT referral pathway
Mike Tadman
Mike Tadman, Senior Specialist Neuroendocrine Cancer Nurse at Oxford...
NETTER-1 update and case presentations
Dr Alia Munir
Dr Alia Munir, Consultant Endocrinologist at Sheffield Teaching Hospitals NHS Foundation Trust ,...
PRRT: revisiting the Lutathera® ([177Lu]Lu-oxodotreotide) SmPC
Dr Gopinath Gnanasegaran
Dr Gopinath Gnanasegaran, Consultant in Nuclear Medicine at the...
Treatment administration
This video explains the process of administration of LUTATHERA ® using the gravity method, including adequate handling...
Dr John Buscombe
Dr John Buscombe, Locum Consultant Physician in Nuclear Medicine at Barts...
Dr John Buscombe
In this 5-minute introductory video, Dr Buscombe provides a brief overview of the PRRT Masterclass and Handbook.
To view a sample of the PRRT Handbook or...